EP Patent

EP2736487B2 — New (trimethoxyphenylamino)pyrimidinyl formulations

Assigned to Rigel Pharmaceuticals Inc · Expires 2024-08-28 · 2y expired

What this patent protects

Patent listed against fostamatinib-disodium.

Drugs covered by this patent

fostamatinib-disodium (FOSTAMATINIB DISODIUM)

Patent Metadata

Patent number: EP2736487B2
Jurisdiction: EP
Classification: —
Expires: 2024-08-28
Drug substance claim: No
Drug product claim: No
Assignee: Rigel Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.